Vivalis Grants Rights to EBx(R) Cell Line for Testing in Production of Viral Vaccines

June 18, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NANTES, FRANCE--(Marketwire - June 18, 2008) - - VIVALIS announced today that it has signed a research license with an animal health company (undisclosed), to evaluate EBx® cell line (EB66) for the production of several viral vaccines.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe